CLINOFIBRATE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C28H36O6
Molecular Weight	468.5818
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(C)(OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(OC(C)(CC)C(O)=O)C=C3)C(O)=O

InChI

InChIKey=BMOVQUBVGICXQN-UHFFFAOYSA-N

InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32)

HIDE SMILES / InChI

Molecular Formula	C28H36O6
Molecular Weight	468.5818
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.google.com/patents/US20110269141

Clinofibrate is known as a fibrate therapeutic drug for hyperlipidemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62 Target ID: Q07869 Gene ID: 5465.0 Gene Symbol: PPARA Target Organism: Homo sapiens (Human) Sources: http://www.springer.com/us/book/9781461475538	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipidemia 82 Sources: http://www.229877.com/article/2013/0823/33410.html	Primary		Approved 8583	LIPOCLIN Approved Use It is usually used to treat hyperlipidemia.

C_max

Value	Dose	Analyte	Population
17.85 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23849436/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11.25 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23849436/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
11 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
27 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
342.24 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23849436/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
351.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23849436/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
240 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
410 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
580 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
20.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18.19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23319135/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	CLINOFIBRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg single, oral Highest studied dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23319135/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/23319135/	Sources: https://pubmed.ncbi.nlm.nih.gov/23319135/
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8301936/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8301936/	Sources: https://pubmed.ncbi.nlm.nih.gov/8301936/

PubMed

Title	Date	PubMed
In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities.	2010-12	20810539
4,4'-(Cyclo-hexane-1,1-di-yl)diphenol methanol solvate.	2009-01-10	21581883
Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts.	2007-09	17645633
A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.	2005-09	16285605
[Usefulness of examination of the cholesterol versus triglyceride ratio for lipoprotein fractions in a patient with marked hyper-triglyceridemia].	2002-10	12451680
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.	2002-01-11	11779144
Effects of some hypolipidemic agents on biochemical values and hepatic peroxisomal enzymes in rats: comparison of probucol, CGA, KCD-232, MLM-160, AL-369 and clinofibrate with clofibrate.	1987-03	3625448

Patents

Sample Use Guides

In Vivo Use Guide

For adults, take 1 tablet (200mg of the active ingredient) at a time, 3 times a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:20:36 GMT 2025` Edited by `admin` on `Mon Mar 31 18:20:36 GMT 2025`
Record UNII	0374EZJ8CU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLINOFIBRATE

Official Name

English

LIPOCLIN

Preferred Name

English

2,2'-(CYCLOHEXYLIDENEBIS(P-PHENYLENEOXY))BIS(2-METHYLBUTYRIC ACID)

Common Name

English

CLINOFIBRATE [JAN]

Common Name

English

Clinofibrate [WHO-DD]

Common Name

English

clinofibrate [INN]

Common Name

English

CLINOFIBRATE [MI]

Common Name

English

CLINOFIBRATE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98150